Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee.

Autor:	Hilmer, Sarah N., Schwartz, Janice, Petrovic, Mirko, Walker, Lauren E., Thürmann, Petra, Le Couteur, David G.
Předmět:	CLINICAL drug trials PHARMACOLOGY ELDER care BIOLOGICAL models MIDDLE-income countries MEDICAL technology CLINICAL trials FRAIL elderly ARTIFICIAL intelligence MEDICAL care TREATMENT effectiveness AGE distribution POLYPHARMACY TRANSLATIONAL research CAREGIVERS MEDICAL research GERIATRIC assessment COGNITION disorders PHARMACOKINETICS DRUG development CONSUMER activism INDIVIDUALIZED medicine DRUG utilization COMORBIDITY ACCIDENTAL falls LOW-income countries OLD age
Zdroj:	Journal of the American Geriatrics Society; Sep2024, Vol. 72 Issue 9, p2942-2950, 9p
Abstrakt:	The International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee aims to improve the use of drugs in older adults and develop new therapeutic approaches for the syndromes and diseases of old age through advocacy, education, and research. In the present paper, we propose strategies relevant to drug development and evaluation, spanning preclinical and the full range of clinical studies. Drugs for older adults need to consider not only age, but also other characteristics common in geriatric patients, such as multimorbidity, polypharmacy, falls, cognitive impairment, and frailty. The IUPHAR Geriatric Committee's position statement on 'Measurement of Frailty in Drug Development and Evaluation' is included, highlighting 12 key principles that cover the spectrum of translational research. We propose that where older adults are likely to be major users of a drug, that frailty is measured at baseline and as an outcome. Preclinical models that replicate the age, frailty, duration of exposure, comorbidities, and co‐medications of the proposed patients may improve translation. We highlight the potential application of recent technologies, such as physiologically based pharmacokinetic–pharmacodynamic modeling informed by frailty biology, and Artificial Intelligence, to inform personalized medicine for older patients. Considerations for the rapidly aging populations in low‐ and middle‐income countries related to health‐care and clinical trials are outlined. Involving older adults, their caregivers and health‐care providers in all phases of research should improve drug development, evaluation, and outcomes for older adults internationally. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text